Episode Description
🧠 Clinical Context:
Subclinical atrial fibrillation = asymptomatic episodes of AF detected by implantable monitors or Holters, lasting 6 minutes to 24 hours.
Big Question: Should we anticoagulate these patients?
🧪 Study Highlights – ARTESiA Trial:
Design: 4,012 patients (mean age 76.8), randomized to apixaban 5 mg BID vs ASA 81 mg daily.
Inclusion: Age >55 with or without history of stroke/TIA; device-confirmed subclinical AF.
📈 Outcomes:
Primary endpoint: Stroke or systemic embolism.
With prior stroke/TIA:
Apixaban significantly reduced events: 1.2% vs 3.4% annually.
Without prior stroke/TIA:
No significant difference: 0.74% (apixaban) vs 1.07% (ASA).
🧩 Clinical Pearls:
Don’t reflexively anticoagulate all device-detected AF — stratify by stroke history.
Consider CHA₂DS₂-VASc, but more importantly, patient-specific functional risk.
Use the Modified Rankin Scale to contextualize why stroke prevention matters:
0 = no symptoms, 5 = severe disability, 6 = death.
Patient framing tip: “If a stroke leaves you unable to walk, speak, or go to the bathroom independently, would that be worth preventing with a pill?”